A team of researchers analyzed data from 101,257 French adults whose median age was 42 from the NutriNet-Santé study to check the association between the consumption of sugary drinks and various forms of cancer.
The drinks included sugar-sweetened beverages such as soft drinks, syrups, fruit drinks, 100% fruit juices without added sugar, milk-based sugary drinks, sports drinks, and energy drinks.
Having analyzed the available data, the researchers concluded that a daily increase of 100 ml in the intake of this type of drinks associated with the higher risk of developing cancer by 18%, and the breast cancer risk raise by 22%.
A new study from the US looks at the body’s antitumor inflammatory response to devise a blood test that can be used to predict the chances of breast cancer recurrence.
For their research, a team of scientists recruited 40 breast cancer survivors and followed them for a period of 4 years, on average. They also used an additional sample of 38 breast cancer survivors to attempt to replicate their findings from the previous group.
The senior author of the study Dr. Peter P. Lee, chair of the Department of Immuno-Oncology at the City of Hope Comprehensive Cancer Center, in Duarte, says: “This is the first success [in] linking a solid tumor with blood biomarkers — an indicator of whether a patient will remain in remission.”
According to the new study from the University of Virginia, US, an unhealthy and inflamed gut microbiome may be the cause of breast cancer to become more aggressive and develop more quickly spreading to other parts of the body.
In the course of the study, the researcher Melanie Rutkowski, PhD, from the University of Virginia Cancer Center with the help of mouse model found that disrupting the microbiome lead to hormone receptor-positive breast cancer to become more aggressive.
The researcher comments: “When we disrupted the microbiome’s equilibrium in mice by chronically treating them antibiotics, it resulted in inflammation systemically and within the mammary tissue. In this inflamed environment, tumor cells were much more able to disseminate from the tissue into the blood and to the lungs, which is a major site for hormone receptor-positive breast cancer to metastasize.”
Recent British research, presented at the National Cancer Research Institute annual conference in the UK, suggests that women who are early risers have lower chances to develop breast cancer.
To study the link between sleep habits and breast cancer, researchers analyzed two data banks with more than 409,000 women. The scientists concluded that early risers had a 40% lower risk of developing breast cancer compared to night owls.
Rebecca Richmond, a research fellow in the Cancer Research U.K. Integrative Cancer Epidemiology Program at the University of Bristol, says: “We would like to do further work to investigate the mechanisms underpinning these results, as the estimates obtained are based on questions related to morning or evening preference, rather than actually whether people get up earlier or later in the day.”
Cancer has a double-edged strategy to get past the macrophages, the largest immune cells in the body. However, the scientists from the Brigham and Women’s Hospital in Boston, US, might have found a way to outwit cancer cells.
A team of researchers developed a “supramolecule”, a chemical structure made of smaller molecules bond together similar to LEGO pieces. This molecule is able to block cancer cells’ specific signals. The researchers tested the supramolecule on mouse models with aggressive breast and skin cancer. The mice treated with the created molecule demonstrated complete inhibition of tumor growth and of formation of metastatic nodules.
Lead author of the study Ashish Kulkarni, an assistant professor in the Department of Chemical Engineering at University of Massachusetts, says: “Clinicians are increasingly realizing that one drug or one-size-fits-all approach is not enough when combating cancer and that a combination immunotherapy, such as blocking two distinct targets in the same immune cell, is the future of immunology. Our approach capitalizes on this concept.”